Greywolf Therapeutics
Kreshnik Hoxha is an experienced professional in the field of Chemistry, with a focus on CMC (Chemistry, Manufacturing, and Controls) and clinical supply chain management. Currently serving as the Head of CMC & Clinical Supply Chain at Greywolf Therapeutics, Kreshnik leads the Global CMC strategy, overseeing CDMO selection, formulation development, and regulatory interactions. Prior roles include Director of CMC at Healx, where Kreshnik managed CMC activities for small molecule portfolios in rare diseases, and Senior Technical Project Manager at Consilient Health, focusing on formulation development and process validation. Additional experience includes positions at Thermo Fisher Scientific and Indivior, emphasizing drug product development and formulation science. Kreshnik holds a PhD in Crystallography and Crystal Engineering from the University of Hull, complemented by a Master's degree in Chemistry with Nanotechnology from the same institution.
This person is not in any teams
Greywolf Therapeutics
Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly. We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.